Mayinglong Pharmaceutical Group Co Ltd operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Mayinglong Pharmaceutical Group Co Ltd with three other
companies in this sector in CHINA :
Xiangxue Pharmaceutical Co Ltd
sales of 2.79 billion Chinese Renmimbi [US$408.29 million]
of which 49%
was Chinese Herbal Medicines),
Autobio Diagnostics Co Ltd
(2.68 billion Chinese Renmimbi [US$392.64 million]
of which 97%
was In vitro diagnosis), and
Guizhou Bailing Group Pharmaceutical Company Limited
(2.85 billion Chinese Renmimbi [US$417.72 million]
of which 84%
Mayinglong Pharmaceutical Group Co Ltd reported sales of 2.70 billion Chinese Renmimbi (US$396.33 million)
December of 2019.
increase of 23.1%
versus 2018, when the company's sales were 2.20 billion Chinese Renmimbi.
Sales of Pharmaceutical Circulation saw an increase
that was more than double the company's growth rate: sales were up
47.7% in 2019, from
737.17 million Chinese Renmimbi to 1.09 billion Chinese Renmimbi.
Not all segments of Mayinglong Pharmaceutical Group Co Ltd experienced an increase in sales in 2019:
sales of Undistributed Amount fell 68.9% to 25,896.81 Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Mayinglong Pharmaceutical Group Co Ltd also experienced decreases in sales in
the Hospital Diagnosis and Treatment (down 22.7% to 159.82 million Chinese Renmimbi)